#Primary Sclerosing Cholangitis Market share | Explore Tumblr posts and blogs

businessindustry · 11 days ago

Text

Primary Sclerosing Cholangitis Market Size, Share and Future News by 2025-2033

The Reports and Insights, a leading market research company, has recently releases report titled “Primary Sclerosing Cholangitis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033.” The study provides a detailed analysis of the industry, including the global Primary Sclerosing Cholangitis Market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Report Highlights:

How big is the Primary Sclerosing Cholangitis Market?

The global primary sclerosing cholangitis market was valued at US$ 174.9 Million in 2024 and is expected to register a CAGR of 7.8% over the forecast period and reach US$ 370.8 Million in 2033.

What are Primary Sclerosing Cholangitis?

Primary sclerosing cholangitis (PSC) is a chronic liver condition characterized by ongoing inflammation and scarring of the bile ducts, leading to their narrowing, obstruction, and subsequent liver damage. Symptoms may include jaundice, itching, abdominal pain, and fatigue. PSC is often linked to an increased risk of liver cirrhosis and liver cancer. While the precise cause remains unclear, the disease is thought to involve autoimmune mechanisms and is frequently associated with inflammatory bowel diseases like ulcerative colitis. Treatment aims to alleviate symptoms, slow disease progression, and manage complications, with liver transplantation being a potential option for advanced stages.

Request for a sample copy with detail analysis: https://www.reportsandinsights.com/sample-request/2389

What are the growth prospects and trends in the Primary Sclerosing Cholangitis industry?

The primary sclerosing cholangitis (PSC) market growth is driven by various factors and trends. The market for primary sclerosing cholangitis (PSC) is expanding due to heightened awareness of the disease, improvements in diagnostic methods, and advancements in treatment options. Increasing recognition of PSC, particularly its links to inflammatory bowel diseases, along with the growing incidence of liver complications, is boosting demand for effective therapies. Key players in the market include pharmaceutical and biotechnology companies focusing on new drug developments and clinical trials. The market is also driven by the need for improved symptom management and potential curative approaches, such as liver transplantation. Despite challenges like high treatment costs and limited available therapies, ongoing research and innovation are contributing to the market's growth. Hence, all these factors contribute to primary sclerosing cholangitis (PSC) market growth.

What is included in market segmentation?

The report has segmented the market into the following categories:

By Type

Classic PSC

Variant PSC

PSC Associated with Autoimmune Hepatitis

PSC with Cholangiocarcinoma

By Treatment Type

Ursodeoxycholic Acid

Obeticholic Acid

Methotrexate

Corticosteroids

Others

By Route of Administration

Oral

Parental

Others

By End-User

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

North America

United States

Canada

Europe

Germany

United Kingdom

France

Italy

Spain

Russia

Poland

Benelux

Nordic

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

ASEAN

Australia & New Zealand

Rest of Asia Pacific

Latin America

Brazil

Mexico

Argentina

Middle East & Africa

Saudi Arabia

South Africa

United Arab Emirates

Israel

Rest of MEA

Who are the key players operating in the industry?

The report covers the major market players including:

Acorda Therapeutics, Inc.

Gilead Sciences, Inc.

NGM Biopharmaceuticals, Inc.

Intercept Pharmaceuticals, Inc.

Falk Pharma GmbH

Allergan Plc.

Shire Plc.

Durect Corporation

Conatus Pharmaceuticals, Inc.

Sirnaomics, Inc.

Shenzhen HighTide Biopharmaceutical Ltd.

Cymabay Therapeutics

Pliant Therapeutics

Immunic AG

View Full Report: https://www.reportsandinsights.com/report/Primary Sclerosing Cholangitis-market

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

Reports and Insights consistently mееt international benchmarks in the market research industry and maintain a kееn focus on providing only the highest quality of reports and analysis outlooks across markets, industries, domains, sectors, and verticals. We have bееn catering to varying market nееds and do not compromise on quality and research efforts in our objective to deliver only the very best to our clients globally.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Reports and Insights Business Research Pvt. Ltd. 1820 Avenue M, Brooklyn, NY, 11230, United States Contact No: +1-(347)-748-1518 Email: [email protected] Website: https://www.reportsandinsights.com/ Follow us on LinkedIn: https://www.linkedin.com/company/report-and-insights/ Follow us on twitter: https://twitter.com/ReportsandInsi1

#Primary Sclerosing Cholangitis Market share #Primary Sclerosing Cholangitis Market size #Primary Sclerosing Cholangitis Market trends

0 notes

marketinsightt · 1 month ago

Text

IgG4-Related Disease Market Size, Share, Key Drivers, Trends, Challenges and Competitive Analysis

Global IgG4-Related Disease Market - Size, Share, Demand, Industry Trends and Opportunities

Global IgG4-Related Disease Market, By Disease Type (Type 1 (IgG4-Related) Autoimmune Pancreatitis (AIP), Retroperitoneal Fibrosis, IgG4-Related Tubulointerstitial Nephritis (TIN), IgG4-Related Sclerosing Cholangitis IgG4-Related Dacryoadenitis and Sialadenitis, IgG4-Related Pachymeningitis, IgG4-Related Thyroid Disease, Serum IgG4 Concentration, and Others), Type (Diagnostic and Treatment), Route of Administration (Parenteral, Oral and Others), End-User (Hospitals, Specialty Clinics, and Others) Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others) – Industry Trends.

Data Bridge Market Research analyses that the global IgG4-related disease market, which was USD 3.63 billion in 2023, is expected to reach USD 4.92 billion by 2031, at a CAGR of 3.9% during the forecast period 2024 to 2031.

Access Full 350 Pages PDF Report @

**Segments**

- By Type: Based on type, the IgG4-related disease market can be segmented into type 1 autoimmune pancreatitis, type 2 autoimmune pancreatitis, Mikulicz disease, and IgG4-related tubulointerstitial nephritis.

- By Diagnosis: In terms of diagnosis, the market can be classified into imaging studies (CT, MRI, PET/CT), laboratory tests (serum IgG4 levels, ESR, CRP), biopsy, and others.

- By Treatment: The treatment segment can be divided into medication (corticosteroids, immunosuppressants), surgery, and others (radiation therapy, plasmapheresis).

**Market Players**

- F. Hoffmann-La Roche Ltd.

- Novartis AG

- Eli Lilly and Company

- Takeda Pharmaceutical Company Limited

- AbbVie Inc.

- Bristol-Myers Squibb Company

- AstraZeneca

- Pfizer Inc.

- Amgen Inc.

- Johnson & Johnson

- GlaxoSmithKline plc

- Sanofi

- Merck & Co., Inc.

- Biogen

- Celgene Corporation

The IgG4-related disease market is characterized by advancements in diagnostic techniques, increasing awareness among healthcare professionals, and a growing number of clinical trials to develop novel treatment options. The rising prevalence of IgG4-related disease is a key factor driving market growth. Additionally, the availability of technologically advanced imaging modalities for accurate diagnosis and increasing investments in research and development activities contribute to the expansion of the market. The segmentation based on type allows for a more targeted approach towards treatment, leading to personalized care for patients. Diagnosis plays a crucial role in the management of IgG4-related disease, with imaging studies and specific laboratory tests aiding in timely detection and appropriate intervention. The treatment segment encompasses various options, including medications and surgical procedures, providing a comprehensive outlook on therapeutic approaches.

The IgG4-related disease market is witnessing significant growth driven by various factors. One of the primary drivers is the increasing prevalence of IgG4-related disease, leading to a higher demand for diagnosis and treatment options. Advances in diagnostic techniques such as imaging studies (CT, MRI, PET/CT) and laboratory tests (serum IgG4 levels, ESR, CRP) have improved the accuracy of diagnosing this condition, thereby boosting market growth. Moreover, growing awareness among healthcare professionals about IgG4-related disease symptoms and risk factors is contributing to early detection and intervention.

Market players in the IgG4-related disease market are actively involved in research and development activities to introduce novel treatment options for patients. Pharmaceutical companies such as F. Hoffmann-La Roche Ltd., Novartis AG, and Eli Lilly and Company are investing in clinical trials to develop innovative medications and therapeutic approaches. The presence of key players like Takeda Pharmaceutical Company Limited, AbbVie Inc., and Bristol-Myers Squibb Company further intensifies competition in the market, leading to a broader range of treatment options for patients.

The segmentation of the IgG4-related disease market based on type and diagnosis allows for a more targeted and personalized approach to managing the condition. Different types of IgG4-related diseases require specific treatment strategies, and accurate diagnosis is essential for determining the most appropriate course of action. The availability of multiple treatment options, including medications (corticosteroids, immunosuppressants), surgery, and other modalities like radiation therapy and plasmapheresis, provides healthcare providers with a diversified toolkit to address the needs of patients effectively.

Technological advancements in imaging modalities and laboratory tests continue to play a crucial role in the diagnosis and monitoring of IgG4-related disease. The integration of artificial intelligence and machine learning in diagnostic tools is facilitating quicker and more accurate assessments, leading to improved patient outcomes. Furthermore, collaborative efforts between market players, research institutions, and healthcare organizations are**Global IgG4-Related Disease Market Analysis:**

The Global IgG4-Related Disease Market is witnessing significant growth due to several key factors. The increasing prevalence of IgG4-related disease is a primary driver for market expansion, leading to a higher demand for advanced diagnostic techniques and innovative treatment options. Advancements in imaging studies (CT, MRI, PET/CT) and laboratory tests (serum IgG4 levels, ESR, CRP) have improved the accuracy of diagnosis, fostering market growth. Additionally, the rising awareness among healthcare professionals about IgG4-related disease symptoms and risk factors is aiding in early detection and timely intervention.

Market players such as F. Hoffmann-La Roche Ltd., Novartis AG, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, and others are actively engaged in research and development endeavors to introduce novel treatment options for patients. The competitive landscape of the market is intensified by the presence of key pharmaceutical companies, leading to a broader range of therapeutic approaches for IgG4-related disease management. Collaboration between market players, research institutions, and healthcare organizations is driving innovation and providing new insights into the market.

The segmentation of the market based on disease type, diagnosis, and treatment allows for a personalized and targeted approach towards managing IgG4-related disease. Different types of IgG4-related diseases necessitate specific treatment strategies, emphasizing the importance of accurate diagnosis in determining the most suitable course of action. With multiple treatment options available, including medications (

The IgG4-Related Disease Market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance.

Major Points Covered in TOC:

IgG4-Related Disease Market Overview: It incorporates six sections, research scope, significant makers covered, market fragments by type, IgG4-Related Disease Market portions by application, study goals, and years considered.

IgG4-Related Disease Market Landscape: Here, the opposition in the Worldwide IgG4-Related Disease Market is dissected, by value, income, deals, and piece of the pie by organization, market rate, cutthroat circumstances Landscape, and most recent patterns, consolidation, development, obtaining, and portions of the overall industry of top organizations.

IgG4-Related Disease Profiles of Manufacturers: Here, driving players of the worldwide IgG4-Related Disease Market are considered dependent on deals region, key items, net edge, income, cost, and creation.

IgG4-Related Disease Market Status and Outlook by Region: In this segment, the report examines about net edge, deals, income, creation, portion of the overall industry, CAGR, and market size by locale. Here, the worldwide IgG4-Related Disease Market is profoundly examined based on areas

IgG4-Related Disease Application or End User: This segment of the exploration study shows how extraordinary end-client/application sections add to the worldwide IgG4-Related Disease Market.

IgG4-Related Disease Market Forecast: Production Side: In this piece of the report, the creators have zeroed in on creation and creation esteem conjecture, key makers gauge, and creation and creation esteem estimate by type.

Keyword: Research Findings and Conclusion: This is one of the last segments of the report where the discoveries of the investigators and the finish of the exploration study are given.

The Report Can Answer the Following Questions:

Who are the global key players of IgG4-Related Disease industry? How are their operating situation (capacity, production, price, cost, gross and revenue)?

What are the types and applications of IgG4-Related Disease? What is the market share of each type and application?

What are the upstream raw materials and manufacturing equipment of IgG4-Related Disease? What is the manufacturing process of IgG4-Related Disease?

Economic impact on IgG4-Related Disease industry and development trend of IgG4-Related Disease industry.

What are the key factors driving the global IgG4-Related Disease industry?

What are the key market trends impacting the growth of the IgG4-Related Disease market?

What are the IgG4-Related Disease market challenges to market growth?

What are the IgG4-Related Disease market opportunities and threats faced by the vendors in the global IgG4-Related Disease market?

Browse Trending Reports:

Down and Feather Pillow Market Mobile Personal Emergency Response Systems Market Ectopic Pregnancy Market Diameter Signaling Market Bluetooth Hearing Aids Market Ganglion Cysts Treatment Market Bring Your Own Device Market Point-of-Care (POC) Drug Abuse Testing Market Carbon Nanotubes Market Satellite Backhaul Market

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC : +653 1251 975

Email: [email protected]"

0 notes

shadyzombieanchor · 5 months ago

Link

0 notes

delveinsight12 · 1 year ago

Text

Primary Sclerosing Cholangitis Market Growth Anticipated: Primary Sclerosing Cholangitis Set for Robust Expansion up to 2032, Major Players Include HighTide Biopharma, Dr. Falk Pharma, Albireo, Pliant Therapeutics

In the market landscape of Primary Sclerosing Cholangitis, an impressive surge is expected during the study period spanning 2019 to 2032, according to latest report titled “Primary Sclerosing Cholangitis Market Insights, Epidemiology and Market Forecast, 2032” from DelveInsight. Noteworthy advancements are projected, fueled not only by existing approved therapies but also by the introduction of emerging treatments slated for launch between 2023 and 2032, incremental increase in incidence is reported to impact the market significantly.

The report sheds light on Primary Sclerosing Cholangitis current treatment practices, upcoming drugs in the Primary Sclerosing Cholangitis pipeline, market shares of individual therapies, and the anticipated trajectory of the Primary Sclerosing Cholangitis market size from 2019 to 2032 across the 7MM (the United States, the EU-4 comprising Italy, Spain, France, and Germany, the United Kingdom, and Japan).

Driving Forces Behind the Primary Sclerosing Cholangitis Market Growth

The overall market of Primary Sclerosing Cholangitis (PSC) is expected to boost due to the expected launch of emerging therapy in the forecasted period (2023–2032).

Discover the Anticipated Evolution and Growth of the Market @ Primary Sclerosing Cholangitis Therapeutics Market Forecast

Therapeutic Advancements and Emerging Treatments:

Primary Sclerosing Cholangitis Clinical Trial Progression: The market is set to experience significant growth, driven by the progression of emerging therapies expected for launch between 2023 and 2032. Pioneering companies, including HighTide Biopharma, Dr. Falk Pharma, Albireo, Pliant Therapeutics, and others, are actively engaged in developing novel drugs for potential market entry.

Primary Sclerosing Cholangitis Innovative Therapies: Ongoing research and development activities are fostering the introduction of innovative therapies designed to address the signs and symptoms of Primary Sclerosing Cholangitis. Therapies such as HTD1801, Norursodeoxycholic acid, A3907, PLN-74809 (bexotegrast), and others are driving the Primary Sclerosing Cholangitis market.

Primary Sclerosing Cholangitis Epidemiological Trends and Patient Demographics:

According to DelveInsight analysis, in the US the diagnosed prevalence of Primary Sclerosing Cholangitis is higher in males than females.

According to DelveInsight analysis, in EU4 and the UK, the symptomatic cases of Primary Sclerosing Cholangitis are higher than asymptomatic cases.

Report Features

Details

Geography Coverage

7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Study Period

2019-2032

Market Size

~USD 113 million in 2022

Key Companies

HighTide Biopharma, Dr. Falk Pharma, Albireo, Pliant Therapeutics, and others.

The market size of primary sclerosing cholangitis (PSC) is anticipated to increase during the study period, 2019–2032. The expected launch of therapies will lead to change in market dynamics during the forecast period (2023-2032).

Leading Primary Sclerosing Cholangitis Companies and Emerging Drugs: Pioneering companies such as HighTide Biopharma, Dr. Falk Pharma, Albireo, Pliant Therapeutics, among others, are actively developing novel drugs for potential entry into the Primary Sclerosing Cholangitis market.

Primary Sclerosing Cholangitis Therapeutic Landscape: Key therapies identified for Primary Sclerosing Cholangitis treatment include HTD1801, Norursodeoxycholic acid, A3907, PLN-74809 (bexotegrast), and more.

Primary Sclerosing Cholangitis Overview:

Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by inflammation, scarring (fibrosis), and narrowing of the bile ducts inside and outside the liver. Over time, this progressive condition can lead to liver damage, cirrhosis, and complications such as liver failure, bile duct infections (cholangitis), and an increased risk of bile duct and liver cancer (cholangiocarcinoma).

Cause: The exact cause of PSC is not fully understood. It is believed to involve an autoimmune component, where the body's immune system mistakenly attacks the bile ducts, leading to inflammation and scarring. PSC is also associated with other autoimmune conditions such as inflammatory bowel disease (IBD), particularly ulcerative colitis.

Symptoms: Many individuals with PSC initially have no symptoms (asymptomatic), but as the disease progresses, they may experience fatigue, itching (pruritus), jaundice (yellowing of the skin and eyes), abdominal pain, fever, weight loss, and complications related to bile duct obstruction or liver damage.

Diagnosis: Diagnosis of PSC involves a combination of blood tests, imaging studies (such as MRI or ERCP), and sometimes a liver biopsy to assess liver tissue for characteristic changes. Additionally, colonoscopy or other tests may be performed to evaluate for associated inflammatory bowel disease.

Treatment: There is no cure for PSC, and treatment primarily focuses on managing symptoms, slowing disease progression, and preventing complications. Medications may be prescribed to relieve itching, manage inflammation, and address complications. In some cases, endoscopic or surgical procedures may be necessary to relieve bile duct blockages.

Monitoring and Complications: Regular monitoring is crucial for individuals with PSC to assess disease progression, manage symptoms, and screen for complications such as liver cirrhosis, bile duct cancer, and other liver-related problems. Liver transplant may be considered for individuals with advanced PSC and severe liver damage or complications.

PSC is a chronic condition that requires ongoing care and monitoring by healthcare providers specializing in gastroenterology or hepatology. Management often involves a multidisciplinary approach, including gastroenterologists, hepatologists, surgeons, and other healthcare professionals, to address various aspects of the disease and optimize treatment strategies.

While treatment can help manage symptoms and slow disease progression, PSC is associated with a risk of complications and may require vigilant long-term management to improve quality of life and reduce the risk of serious liver-related issues.

Key Facts Primary Sclerosing Cholangitis Market Report:

The Primary Sclerosing Cholangitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032).

According to DelveInsight analysis, the United States accounted for the highest market size of $78 million, with significant market share of PSC in 2022 in the 7MM. The market size of the 7MM is anticipated to increase in the forecast period due to the expected launch of emerging therapy.

Among EU4 and the UK, Germany, Italy, and the UK accounted for the highest market size with approximately 25% each of the total market size in the EU4 and the UK in the year 2022, whileSpainaccounted for the lowest market in the year 2022.

As per DelveInsight estimates, the market size in Japan was approximately USD 4 million in 2022. These numbers are expected to increase during the forecasted period.

Primary Sclerosing Cholangitis Epidemiology Insights:

In 2022, there were about 9,171 diagnosed asymptomatic cases of PSC and 11,038 diagnosed symptomatic cases PSC, in the EU4 and the UK.

As per DelveInsight’s analysts, in Japan, there were approximately 2,443 diagnosed prevalent cases of PSC in the year 2022 accounting for nearly 5% of the total diagnosed prevalent cases of PSC in the 7MM.

Primary Sclerosing Cholangitis Epidemiology Segmentation:

The Primary Sclerosing Cholangitis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Primary Sclerosing Cholangitis

• Prevalent Cases of Primary Sclerosing Cholangitis by severity

• Gender-specific Prevalence of Primary Sclerosing Cholangitis

• Diagnosed Cases oF Primary Sclerosing Cholangitis

For in-depth insights, access the full report @ Primary Sclerosing Cholangitis Market Outlook 2032

Related Reports:

Primary Sclerosing Cholangitis Epidemiology Forecast

Primary Sclerosing Cholangitis Epidemiology Forecast report delivers an in-depth understanding of the Primary Sclerosing Cholangitis, historical and forecasted epidemiology in the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Primary Sclerosing Cholangitis Pipeline Insight

Primary Sclerosing Cholangitis Pipeline Insight report provides comprehensive insights about companies and pipeline drugs in the Primary Sclerosing Cholangitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.

Healthcare Consulting and Market Research Services by DelveInsight

Upgrade your industry insights with our comprehensive medical devices market assessment reports. Visit to gain a strategic edge through expert analysis and in-depth coverage of the latest trends, innovations, and market dynamics @ Healthcare Market Research Services

About DelveInsight:

DelveInsight is a prominent business consultant and market research firm specializing in the life sciences sector. With a focus on supporting pharmaceutical companies, DelveInsight provides end-to-end solutions to enhance their performance.

Connect with DelveInsight:

LinkedIn | Facebook | Twitter

Kritika Rehani

[email protected]

+91-9650213330

www.delveinsight.com

0 notes

kritikarehani · 5 years ago

Text

Primary Sclerosing Cholangitis (PSC) Market Trends 2030

Primary Sclerosing Cholangitis (PSC) is a condition that affects the bile ducts. It occurs because of inflammation in the bile ducts (cholangitis) that leads to scarring (sclerosis) and narrowing of the ducts. As a result, bile cannot be released to the gallbladder and small intestine, and it builds up in the liver.

DelveInsight's "Primary Sclerosing Cholangitis (PSC) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Primary Sclerosing Cholangitis (PSC), historical and forecasted epidemiology as well as the Primary Sclerosing Cholangitis (PSC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Primary Sclerosing Cholangitis (PSC) market report provides current treatment practices, emerging drugs, Primary Sclerosing Cholangitis (PSC) market share of the individual therapies, current and forecasted Primary Sclerosing Cholangitis (PSC) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Primary Sclerosing Cholangitis (PSC) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

· The United States

· EU5 (Germany, France, Italy, Spain, and the United Kingdom)

· Japan

Study Period: 2017-2030

Download sample pages: https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market

Primary Sclerosing Cholangitis (PSC) Disease Understanding and Treatment Algorithm

Primary Sclerosing Cholangitis is thought to arise from a combination of genetic and environmental factors. Researchers believe that genetic changes play a role in this condition because it often occurs in several members of a family and because immediate family members of someone with primary sclerosing cholangitis have an increased risk of developing the condition.

The symptoms associated with PSC include fatigue and itching (pruritus), followed by yellowing of the skin, mucous membranes, and whites of the eyes (jaundice). Other symptoms may include losing weight without trying, poor appetite, fever, and pain in the abdomen.

The DelveInsight Primary Sclerosing Cholangitis (PSC) market report gives a thorough understanding of the Primary Sclerosing Cholangitis (PSC) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Primary Sclerosing Cholangitis (PSC).

Treatment

It covers the details of conventional and current medical therapies available in the Primary Sclerosing Cholangitis (PSC) market for the treatment of the condition. It also provides Primary Sclerosing Cholangitis (PSC) treatment algorithms and guidelines in the United States, Europe, and Japan.

Request for sample pages: https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market

Primary Sclerosing Cholangitis (PSC) Epidemiology

The Primary Sclerosing Cholangitis (PSC) epidemiology division provide insights about historical and current Primary Sclerosing Cholangitis (PSC) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key facts:

• Primary sclerosing cholangitis is a rare disorder that affects males twice as often as females. Although it may affect individuals of any age, the disorder most often occurs in middle-aged adults.

• The exact incidence and prevalence of the disorder is unknown. One estimate places the incidence at approximately 1 person per each 100,000 in the general population in the United States or Europe.

Primary Sclerosing Cholangitis (PSC) Drug Chapters

In the coming years, the competitive landscape for the Primary Sclerosing Cholangitis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

Major players, such as Gilead Sciences, HighTide Therapeutics, Tobira Therapeutics and NGM Biopharmaceuticals are involved in developing therapies for Primary Sclerosing Cholangitis. Launch of emerging therapies, such as GS-9674 (Gilead Sciences), HTD1801 (HighTide Therapeutics), Cenicriviroc (Tobira Therapeutics) and NGM282 (NGM Biopharmaceuticals) will significantly impact the Primary Sclerosing Cholangitis market during the study period (2017–2030).

Drug chapter segment of the Primary Sclerosing Cholangitis (PSC) report encloses the detailed analysis of Primary Sclerosing Cholangitis (PSC) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Primary Sclerosing Cholangitis (PSC) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Primary Sclerosing Cholangitis (PSC) treatment.

Primary Sclerosing Cholangitis (PSC) Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Primary Sclerosing Cholangitis (PSC) treatment.

Primary Sclerosing Cholangitis (PSC) Market Outlook

The treatment of PSC focuses on managing the complications and monitoring the liver damage. There have been several medications which are studied in people with Primary Sclerosing Cholangitis, but so far none have been found to slow or reverse the liver damage associated with this disease.

The pharmacotherapy is aimed at treating symptoms and managing complications. Immuno-suppressants, bile salts, chelators (eg, cholestyramine for pruritus), and steroids are used in an attempt to control the disease process but have not shown significant benefit. The further treatment depends on the stage and degree of progression of the disease. There are two major treatment goals in PSC: slow or reverse disease progression and management of symptoms of disease progression.

The Primary Sclerosing Cholangitis (PSC) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Primary Sclerosing Cholangitis (PSC) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

According to DelveInsight, Primary Sclerosing Cholangitis (PSC) market in 7MM is expected to change in the study period 2017-2030.

Click here and get access to our full report.

Click here and request to download our sample pages.

#Primary Sclerosing Cholangitis (PSC) market #Primary Sclerosing Cholangitis (PSC) market share #Primary Sclerosing Cholangitis (PSC) market size #Primary Sclerosing Cholangitis (PSC) market trends #Primary Sclerosing Cholangitis (PSC) market research reports #Primary Sclerosing Cholangitis (PSC) key companies #Primary Sclerosing Cholangitis (PSC) epidemiology #Primary Sclerosing Cholangitis (PSC) symptoms #Primary Sclerosing Cholangitis (PSC) treatment

0 notes

latestmarketresearchreports · 4 years ago

Text

Primary Sclerosing Cholangitis Treatment Market Size, Share, Trends, Growth - Forecast and Analysis 2020-2024

Primary Sclerosing Cholangitis Treatment Market will register a CAGR of 4% during 2020-2024. The market’s growth momentum will Accelerate.

rise in number of liver transplants and UDCA treatment | Increasing incidence of diseases associated with primary sclerosing cholangitis | Growth in the availability of treatment will be one of the major factors driving the growth of this market. Additionally, key Primary Sclerosing Cholangitis Treatment Market trends such as the increasing incidence of diseases associated with primary sclerosing cholangitis will also influence market growth during the forecast period.

Primary Sclerosing Cholangitis Treatment Market Size

Get a FREE sample for more insights on the growth and the market share of various regions

During the forecast period, the Primary Sclerosing Cholangitis Treatment Market size will grow by $ 37.50 mn.

Primary Sclerosing Cholangitis Treatment Market : Vendors

The market is fragmented and owing to the growth opportunities, the level of competition among the companies in this market space will intensify further. are some of the major companies in the Primary Sclerosing Cholangitis Treatment Market. Though the forecast period offers opportunities for vendors to increase their market share, factors such as the poor understanding of primary sclerosing cholangitis pathogenesis | Late detection of primary sclerosing cholangitis | Overlap syndromes create problems during diagnosis will also challenge the growth of the companies.

are some of the companies covered in Technavio’s Primary Sclerosing Cholangitis Treatment Market report for 2020-2024.

Primary Sclerosing Cholangitis Treatment Market : Region-level Analysis

The report identifies region-level market dynamics, developments, and key markets. The regional level analysis also identifies the market share, growth momentum, and key leading countries in the Primary Sclerosing Cholangitis Treatment Market.

The North America will account for the largest Primary Sclerosing Cholangitis Treatment Market share and during 2020-2024, the region will contribute to 47% of the market’s growth.

Our Custom Research Solutions can provide tailored Primary Sclerosing Cholangitis Treatment Market information to meet your specific requirements.

0 notes

healtcare · 4 years ago

Text

Global Haematology and Flow Cytometry Market

Global Haematology and Flow Cytometry Market is expected to reach $XX Mn by 2026 from $XX Mn in 2019, at a CAGR of 8.5% during forecast period.

Global Haematology and Flow Cytometry Market Overview:

Hematology is a medical specialty that deals with the study and treatment of blood. This is concerned with the diagnosis, study, treatment, and prevention of blood diseases. Flow cytometry is an analytical tool that is used in the measurement and analysis of several physical characteristics of cells or particles suspended in a fluid using a laser beam. The method helps to subclassify cell types to decide on the best treatment plan.

Global Haematology and Flow Cytometry Market Dynamics:

Rising global incidence and prevalence of chronic diseases like blood cancer is the major driving factor for the market growth. According to the National Cancer Institute in 2018, it was being estimated that 60,300 new leukemia cases are diagnosed and the deaths are around 24,470 cases in the United States. The increasing number of HIV cases globally is an important driver for the flow cytometry market. This is because the flow cytometry technique has its direct application in HIV diagnosis. According To UNAIDS in 2017, 31.1-43.9 million people globally are living with HIV by out of which 1.8 million are newly affected with HIV. Flow cytometry uses light scattering to determine the identity of cells. Increasing adoption of flow cytometry techniques in research and academia and growing initiatives in the field of immunology and Immuno-oncology researches are expected to propel the growth of the global flow cytometry market. Growth in stem cell research and the development of high-throughput flow cytometry technologies are likely to add new opportunities for this market in the coming years. Increasing regulatory approval and the introduction of technologically advanced flow cytometry solutions are expected to facilitate market growth over the forecast period. For instance, in June 2020, Sysmex Corporation launched the XF-1600 flow cytometer for laboratories, in North America. A significant restraint on the flow cytometry market is the availability of cheaper and better alternatives. ELISA (enzyme-linked immunosorbent assay) and radioimmunoassay are two of these alternatives. Although flow cytometry, ELISA, and radioimmunoassay are all methods for detecting "problem cells" in a community of cells, ELISA and radioimmunoassay are less expensive and easier to use. Along with this, the dearth of skilled technicians for managing such advanced technology is expected to restrain the market growth. The report has profiled twenty key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.

Global Haematology and Flow Cytometry Market Segment Analysis:

The Global Haematology and Flow Cytometry Market is segment on the basis of Product, Technology and End-Users. Based on Product, the flow cytometry instruments segment is expected to dominate the global market. The segment is further classified into cell analyzers and cell sorters. It held a market share of 25% in 2020. This high share is attributed to new advancements in technology and the introduction of novel cytometers by key players. The high price of these instruments is also contributing toward the high revenue generation in this segment. Along with this, reagents and consumables also held a prominent share in 2020. Owing to their increased adoption in diagnostics and research the segment is expected to register lucrative growth over the forecast period. The large share of this segment is mainly attributed to the growing research activities to develop and prove the efficacy of various assays and kits, and the commercialization of high-quality and application-specific consumables, reagents, and assays. Based on technology, the cell-based flow cytometry segment held the largest market share of 76% in 2020. The highest share is due to an increase in demand for early diagnosis and increased understanding of the related benefits of cell-based assays. In addition, advances in cell-based assay technology, such as innovations in tools, labels, affinity reagents, software, and algorithms, are expected to accelerate adoption in the coming years. To know about the Research Methodology :- Request Free Sample Report

Global Haematology and Flow Cytometry Market Regional Insights:

North America dominated the global market in 2020. The region dominated the global market in 2020 by holding a market share of 39.1%. This dominance is attributed due to the United States' high healthcare spending, well-developed healthcare system, and widespread adoption of technologically advanced flow cytometry solutions. In addition, the established pharmaceutical industry, as well as extensive research activities by research universities and pharmaceutical companies has generated huge demand for flow cytometry solutions for research universities and pharmaceutical companies have created a huge demand for flow cytometry solutions for research needs. APAC region is projected to exhibit highest CAGR during forecast period. This high growth can be attributed to the extensive growth in the pharmaceutical and biotechnology industries of emerging economies, such as China and India. The lucrative growth exhibited by this region is also an outcome of continuous government support for the establishment of the pharmaceutical industry in emerging countries. The report also helps in understanding Global Haematology and Flow Cytometrys Market dynamics, structure by analyzing the market segments and project the Global Haematology and Flow Cytometrys Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Haematology and Flow Cytometrys Market make the report investor’s guide.

Global Haematology and Flow Cytometry Market, key developments:

• In September 2018, the U.S. FDA awarded a grant of ~$18 million over a period of four years for 12 new clinical trials. These clinical trials are aimed at developing products for patients with rare diseases (including primary sclerosing cholangitis, stargardt disease, Cushing disease, acute myeloid leukemia, and graft versus host disease, among others). • In March 2017, Cytek Biosciences Inc., a manufacturer and supplier of flow cytometry products and services launched its DxP Athena flow cytometry system. The system is compact, powerful, easy-to-use cell analyzer that are typically only found in conventional instruments that come with a much higher price tag. The DxP Athena makes the benefits of flow cytometry which are more readily available to larger number of researchers by its compact size. • In 2016, the Global Clinical Trials Fund (U.K.) launched a dedicated fund with an upper limit of $662,185 to support clinical trials across the world related to the testing of new experimental drugs and existing drugs developed for dementia.

Global Haematology and Flow Cytometry Market Scope: Inquire before buying

Global Haematology and Flow Cytometry Market, by Region:

• North America • Europe • South America • MEA • APAC

Global Haematology and Flow Cytometry Market, Key players:

• Becton, Dickinson and Company • Beckman Coulter, Inc. • Bio-Rad Laboratories, Inc. • Thermo Fisher Scientific, Inc. • Merck KGaA • Sysmex Partec GmbH • Luminex Corporation • Miltenyi Biotec GmbH • Sony Biotechnology • Abbott • Agilent Technologies • CellaVision • Horiba • Nihon Kohden • Ortho-Clinical Diagnostics • Roche • Siemens Healthineers • Sysmex • Miltenyi Biotec • Apogee Flow Systems Ltd.

#Haematology #Flow Cytometry #Haematology and Flow Cytometry

0 notes

rdagade · 4 years ago

Text

Global Haematology and Flow Cytometry Market

is expected to reach $XX Mn by 2026 from $XX Mn in 2019, at a CAGR of 8.5% during forecast period.

Global Haematology and Flow Cytometry Market Overview:

Global Haematology and Flow Cytometry Market Dynamics:

Increasing adoption of flow cytometry techniques in research and academia and growing initiatives in the field of immunology and Immuno-oncology researches are expected to propel the growth of the global flow cytometry market. Growth in stem cell research and the development of high-throughput flow cytometry technologies are likely to add new opportunities for this market in the coming years. Increasing regulatory approval and the introduction of technologically advanced flow cytometry solutions are expected to facilitate market growth over the forecast period. For instance, in June 2020, Sysmex Corporation launched the XF-1600 flow cytometer for laboratories, in North America. A significant restraint on the flow cytometry market is the availability of cheaper and better alternatives.

ELISA (enzyme-linked immunosorbent assay) and radioimmunoassay are two of these alternatives. Although flow cytometry, ELISA, and radioimmunoassay are all methods for detecting "problem cells" in a community of cells, ELISA and radioimmunoassay are less expensive and easier to use. Along with this, the dearth of skilled technicians for managing such advanced technology is expected to restrain the market growth.

The report has profiled twenty key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.

Global Haematology and Flow Cytometry Market Segment Analysis:

Based on technology, the cell-based flow cytometry segment held the largest market share of 76% in 2020. The highest share is due to an increase in demand for early diagnosis and increased understanding of the related benefits of cell-based assays. In addition, advances in cell-based assay technology, such as innovations in tools, labels, affinity reagents, software, and algorithms, are expected to accelerate adoption in the coming years.

To know about the Research Methodology :-

Request Free Sample Report

Global Haematology and Flow Cytometry Market Regional Insights:

This high growth can be attributed to the extensive growth in the pharmaceutical and biotechnology industries of emerging economies, such as China and India. The lucrative growth exhibited by this region is also an outcome of continuous government support for the establishment of the pharmaceutical industry in emerging countries. The report also helps in understanding Global Haematology and Flow Cytometrys Market dynamics, structure by analyzing the market segments and project the Global Haematology and Flow Cytometrys Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Haematology and Flow Cytometrys Market make the report investor’s guide.

Global Haematology and Flow Cytometry Market, key developments:

For more information visit@ https://www.maximizemarketresearch.com/market-report/global-haematology-and-flow-cytometry-market/98749/

Global Haematology and Flow Cytometry Market Scope: Inquire before buying

Global Haematology and Flow Cytometry Market, by Region:

• North America • Europe • South America • MEA • APAC

Global Haematology and Flow Cytometry Market, Key players:

This report submitted by Maximize market Research Company

Customization of the report:

Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.

About Maximize Market Research:

Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization Address: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: [email protected]

Address: Omkar Heights, Sinhagad Road, Manik Baug, Vadgaon Bk,Pune, Maharashtra 411051, India.

Contact: +919607195908

#Global Haematology and Flow Cytometry Market

0 notes

technavio · 4 years ago

Text

Primary Sclerosing Cholangitis Treatment Market by Product and Geography - Forecast and Analysis 2020-2024

Primary Sclerosing Cholangitis Treatment Market will register a CAGR of 4% during 2020-2024. The market’s growth momentum will Accelerate.

Primary Sclerosing Cholangitis Treatment Market Size

Get a FREE sample for more insights on the growth and the market share of various regions

During the forecast period, the Primary Sclerosing Cholangitis Treatment Market size will grow by $ 37.50 mn.

Primary Sclerosing Cholangitis Treatment Market : Vendors

are some of the companies covered in Technavio’s Primary Sclerosing Cholangitis Treatment Market report for 2020-2024.

Primary Sclerosing Cholangitis Treatment Market : Region-level Analysis

The North America will account for the largest Primary Sclerosing Cholangitis Treatment Market share and during 2020-2024, the region will contribute to 47% of the market’s growth.

Our Custom Research Solutions can provide tailored Primary Sclerosing Cholangitis Treatment Market information to meet your specific requirements.

0 notes

awesomechrisharry · 4 years ago

Text

Primary Sclerosing Cholangitis Treatment Market: Future Demand, Analysis & Outlook to 2025

The research report on Primary Sclerosing Cholangitis Treatment market as well as industry is an in-depth study that provides detailed information of leading players, qualitative analysis and quantitative analysis, types & end-users; historical figures, region analysis, market technology landscape & restraints, strategic planning, and a precise section for the effect of Covid-19 on the industry. Our research analysts intensively determine the significant outlook of the global Primary Sclerosing Cholangitis Treatment market study with regard to primary research & secondary research and they have represented it in the form of figures, pie charts, tables & other pictorial representations for better understanding.

To Know More Details About This Report, Get Sample @ http://www.acquiremarketresearch.com/sample-request/348428

The report on Primary Sclerosing Cholangitis Treatment market claims this industry to emerge as one of the most lucrative spaces in the ensuing years, exhibiting a modest growth rate over the forecast period. Enumerating a highly exhaustive outline of Primary Sclerosing Cholangitis Treatment Market size, this report is also inclusive of the total valuation that the Primary Sclerosing Cholangitis Treatment industry presently holds, a brief segmentation of this market and Primary Sclerosing Cholangitis Treatment market growth opportunities of this industry in addition to its geographical expanse.

Major Key Players Covered In This Report:

Allergan, Glenmark, Impax Laboratories, Mylan, Teva Pharmaceuticals, Dr. Falk Pharma, Daewoong Pharmaceutical, Epic Pharma, Mitsubishi Tanabe Pharma, Lannett, Bruschettini, Shanghai Pharma, Grindeks, Acorda Therapeutics, Gilead Sciences, Intercept Pharmaceuticals, Shire Plc, NGM Biopharmaceuticals, Conatus Pharmaceuticals, Durect Corporation, Sirnaomics, Shenzhen HighTide Biopharmaceuticals

Primary Sclerosing Cholangitis Treatment Market Analysis by 2020

This research report based on ‘Primary Sclerosing Cholangitis Treatment market’ and available with Acquire Market Research includes latest and upcoming market trends in addition to the global spectrum of the ‘Primary Sclerosing Cholangitis Treatment market’ that includes numerous regions. Moreover, the research also expands on intricate details pertaining to contributions by key Manufacturers, import & export, demand and supply analysis as well as industry size, share growth of the Primary Sclerosing Cholangitis Treatment industry.

The specified segments and sub-sections of the market are explained below:

By Product Type:

Liver Transplantation Operation, UDCA Drugs, PSC Drugs

By Application/End-user:

Hospital, Clinics, Other

By country/region:

North America

Europe

Asia-Pacific

South America

Middle East and Africa

Check Discount @ http://www.acquiremarketresearch.com/discount-request/348428

Frequently Asked Questions About This Market Research Report:

What are the latest trends, and strategies followed by leadings companies?

What is the market share of each Major Players specified in this report?

What are opportunities for Primary Sclerosing Cholangitis Treatment investors and market aspirants?

What are the major product types and which applications are known?

Which countries are analyzed in this report?

What is the market size, and demand for Primary Sclerosing Cholangitis Treatment on a global level?

What is the CAGR value of Primary Sclerosing Cholangitis Treatment Market?

About Us:

Acquire Market Research is a market research-based company empowering companies with data-driven insights. We provide Market Research Reports with accurate and well-informed data, Real-Time with Real Application. A good research methodology proves to be powerful and simplified information that applied right from day-to-day lives to complex decisions helps us navigate through with vision, purpose and well-armed strategies. At Acquire Market Research, we constantly strive for innovation in the techniques and the quality of analysis that goes into our reports.

http://www.acquiremarketresearch.com/

[email protected]

#Primary Sclerosing Cholangitis Treatment #Primary Sclerosing Cholangitis Treatment market

0 notes

businessindustry · 2 months ago

Text

Primary Sclerosing Cholangitis Market Size, Share and Future News by 2025-2033

Report Highlights:

How big is the Primary Sclerosing Cholangitis Market?

The global primary sclerosing cholangitis market was valued at US$ 174.9 Million in 2024 and is expected to register a CAGR of 7.8% over the forecast period and reach US$ 370.8 Million in 2033.

What are Primary Sclerosing Cholangitis?

Request for a sample copy with detail analysis: https://www.reportsandinsights.com/sample-request/2389

What are the growth prospects and trends in the Primary Sclerosing Cholangitis industry?

What is included in market segmentation?

The report has segmented the market into the following categories:

By Type

Classic PSC

Variant PSC

PSC Associated with Autoimmune Hepatitis

PSC with Cholangiocarcinoma

By Treatment Type

Ursodeoxycholic Acid

Obeticholic Acid

Methotrexate

Corticosteroids

Others

By Route of Administration

Oral

Parental

Others

By End-User

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

North America

United States

Canada

Europe

Germany

United Kingdom

France

Italy

Spain

Russia

Poland

Benelux

Nordic

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

ASEAN

Australia & New Zealand

Rest of Asia Pacific

Latin America

Brazil

Mexico

Argentina

Middle East & Africa

Saudi Arabia

South Africa

United Arab Emirates

Israel

Rest of MEA

Who are the key players operating in the industry?

The report covers the major market players including:

Acorda Therapeutics, Inc.

Gilead Sciences, Inc.

NGM Biopharmaceuticals, Inc.

Intercept Pharmaceuticals, Inc.

Falk Pharma GmbH

Allergan Plc.

Shire Plc.

Durect Corporation

Conatus Pharmaceuticals, Inc.

Sirnaomics, Inc.

Shenzhen HighTide Biopharmaceutical Ltd.

Cymabay Therapeutics

Pliant Therapeutics

Immunic AG

View Full Report: https://www.reportsandinsights.com/report/Primary Sclerosing Cholangitis-market

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

#Primary Sclerosing Cholangitis Market share #Primary Sclerosing Cholangitis Market size #Primary Sclerosing Cholangitis Market trends

0 notes

stanleystangele · 5 years ago

Text

Primary Sclerosing Cholangitis Treatment Market: Future Demand, Analysis & Outlook to 2025

To Know More Details About This Report, Get Sample @ http://www.acquiremarketresearch.com/sample-request/347806

Major Key Players Covered In This Report:

Primary Sclerosing Cholangitis Treatment Market Analysis by 2020

The specified segments and sub-sections of the market are explained below:

By Product Type:

Liver Transplantation Operation, UDCA Drugs, PSC Drugs

By Application/End-user:

Hospital, Clinics, Other

By country/region:

North America

Europe

Asia-Pacific

South America

Middle East and Africa

Check Discount @ http://www.acquiremarketresearch.com/discount-request/347806

Frequently Asked Questions About This Market Research Report:

What are the latest trends, and strategies followed by leadings companies?

What is the market share of each Major Players specified in this report?

What are opportunities for Primary Sclerosing Cholangitis Treatment investors and market aspirants?

What are the major product types and which applications are known?

Which countries are analyzed in this report?

What is the market size, and demand for Primary Sclerosing Cholangitis Treatment on a global level?

What is the CAGR value of Primary Sclerosing Cholangitis Treatment Market?

About Us:

http://www.acquiremarketresearch.com/

[email protected]

#Primary Sclerosing Cholangitis Treatment Market #Primary Sclerosing Cholangitis Treatment Market size

0 notes

adwaitcoherent · 5 years ago

Text

By 2026, Ursodeoxycholic Acid Market To Surpass US$ 1,075.5 Million - Coherent Market Insights

Ursodeoxycholic Acid Market To exhibit a CAGR of 10.1% over the forecast period (2018 – 2026).

Request for Sample PDF Copy:

https://www.coherentmarketinsights.com/insight/request-pdf/2199

Description:

Ursodeoxycholic acid (UDCA) is a bile acid taken as either a tablet or liquid to treat gallstones and to treat and prevent progression of cystic fibrosis-related liver disorders. UDCA modifies the bile acid pool by decreasing levels of hydrophobic bile acids while increasing proportion of nontoxic hydrophilic bile acids. UDCA can delay development of gastroesophageal varices and progression to cirrhosis. Moreover, it can improve long-term survival in patients with primary biliary cirrhosis.

Significant improvement in liver health can be achieved through UDCA therapy in patients with intrahepatic cholestasis of pregnancy, primary sclerosing cholangitis, nonalcoholic fatty liver disease, cystic fibrosis-associated liver disease, total parenteral nutrition-induced cholestasis, graft related liver disease, and in some pediatric cholestatic liver diseases.

The global ursodeoxycholic acid market size was valued at US$ 457.3 million in 2017 and is expected to exhibit a CAGR of 10.1% over the forecast period (2018 – 2026).

Figure 1. Global Ursodeoxycholic Acid Market Value (US$ Mn), by Region, 2018

Ursodeoxycholic Acid | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Increasing prevalence of gall stones and cystic fibrosis to propel the ursodeoxycholic acid market growth

Ursodeoxycholic acid is being increasingly used for treatment of chronic cholestatic liver diseases. Increasing prevalence of cystic fibrosis and gall stones is the major factor driving growth of the global ursodeoxycholic acid market during the forecast period. According to the Cystic Fibrosis Foundation 2015 data, around 30,000 people suffered from cystic fibrosis in the U.S. Moreover, around 1,000 new cases of cystic fibrosis are diagnosed in the country, annually. According to the American Gastroenterological Association 2017 report, gallstones is affecting 10-15% of the U.S. population annually, which accounts for around 25 million people.

Women are more likely to develop gallstones in comparison to men. High estrogen levels during pregnancy, birth control pills or hormone replacement therapy are the major factors that produce gallstones in women. Moreover, occurrence of gallstones is also high in older adults and individuals with a family history of gallstones. Surgery is the usual treatment for symptomatic gallstones, however, treatment with ursodeoxycholic acid can dissolve smaller stones, which are made mainly of cholesterol.

However, drawbacks such as low efficacy (around 40%), slowness in action, and possibility of stone recurrence are expected to hinder the market growth.

Figure 2. Global Ursodeoxycholic Acid Market Share (%), by Dosage Form, 2026

Ursodeoxycholic Acid | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Increasing research studies on ursodeoxycholic acid to bolster the market growth

Increasing research studies conducted on application of ursodeoxycholic acid (UDCA) in other disease indications is expected to fuel growth of the global ursodeoxycholic acid market. According to the University of Sheffield August 2018 study, UDCA improves mitochondrial dysfunction, which is known to be a causative factor for both sporadic and familial Alzheimer’s disease.

According to the Cure Parkinson’s Trust, U.K. 2018 article, researchers demonstrated that UDCA could protect dopamine cells grown in culture from apoptosis, or programmed cell death, by regulating a specific cell survival pathway.

According to a study published by National Center for Biotechnology Information (NCBI) in 2016, UDCA can be introduced as a novel approach for management of Parkinson's disease through anti-apoptotic and anti-inflammatory mechanisms.

Moreover, UDCA can reduce the rotenone-induced nuclear factor-κB expression and tumor necrosis factor alpha level with its anti-inflammatory properties.

Key Players

Major players operating in the global ursodeoxycholic acid market include Dipharma Francis Srl, ERREGIERRE S.p.A., Grindeks, Industria Chimica Emiliana, Mitsubishi Tanabe Pharma Corporation, Zhongshan Belling Biotechnology Co., Glenmark Pharmaceutical Limited, Abil Chempharma Private Limited, Biotavia Labs Pvt Ltd, Daewoong Bio Inc., PharmaZell GmbH, and Suzhou Tianlu Bio-pharmaceutical Co., Ltd.

Market players are focused on strategies such as acquisition, in order to expand their offerings and strengthen their market presence in the U.S. For instance, in May 2018, Dipharma Francis Srl acquired Kalexsyn, Inc., a contract research organization (CRO) that provides chemistry services to the biotechnology and pharmaceutical industry. Such strategic moves will strengthen the company’s technical competency in the development of industrial manufacturing processes for active pharmaceutical ingredients (API).

About Us: Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We do offer wide range of services such as Industry analysis, Consulting services, Market Intelligence, Customized research services and much more. We have expertise in many fields such as healthcare, chemicals and materials, Automation, semiconductors, electronics, energy, food and beverage, packaging and many more. Visit our website to know more.

Buy Report Here:

https://www.coherentmarketinsights.com/insight/buy-now/2199

Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave. #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected]

#Market Analysis #Market Research #Coherent Market Insights

0 notes

sallowjac · 5 years ago

Link

0 notes

kritikarehani · 5 years ago

Photo

Symptoms associated with Primary Sclerosing Cholangitis (PSC)

Source: https://www.delveinsight.com/report-store/primary-sclerosing-cholangitis-market

0 notes

kunal9485 · 4 years ago

Text

Primary Sclerosing Cholangitis Market To Gain Significant Revenue in the Period of 2028

The Primary Sclerosing Cholangitis Market Report conveys the clean expounded structure of the Market including every single business-related data of the market at a worldwide level. The total scope of data identified with the Market is acquired through different sources and this got main part of the data is orchestrated, handled, and spoken to by a gathering of authorities through the utilization of various methodological procedures and logical instruments, for example, SWOT analysis to produce an entire arrangement of exchange based examination in regards to the Primary Sclerosing Cholangitis Market.

Rising prevalence of liver diseases coupled with increasing alcohol consumption are attributable to the growth of primary sclerosing cholangitis market. Data Bridge Market Research analyses that the primary sclerosing cholangitis will exhibit a CAGR of around 4.02% for the forecast period of 2021-2028.

Download Free Sample Copy of the Report to Understand the Structure of the Complete Report (Including Full TOC, Table & Figures) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-primary-sclerosing-cholangitis-market

Prominent Key Players – Covered in the report:

Glenmark Pharmaceuticals Limited, Zydus Pharmaceuticals, Inc., Merck & Co., Inc., Sanofi, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited., F. Hoffmann-La Roche Ltd, Abbott, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sandoz International GmbH, Bristol-Myers Squibb Company, Amneal Pharmaceuticals LLC., HighTide Therapeutics Inc., Sirnaomics, Inc., Allergan, Acorda Therapeutics, Inc., Gilead Sciences, Inc. and NGM Biopharmaceuticals. among other domestic and global players. ….

Highlights of the Report?

The report offers a 360-degree overview of the market and emphasizes significant factors promoting, repelling, challenging, and creating opportunities for the market in the forecast duration. The report also lists the names of key players operating in the market and the strategies adopted by them to earn the lion’s share in the market. It also offers interesting insights into the market, current Primary Sclerosing Cholangitis market trends, and major industry developments of the market. The report also discusses the table of segmentation in detail and lists the names of the leading segment with its attributed factors. It is available for sale on the company website.

Market Segment by Regions:

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Primary Sclerosing Cholangitis Market is framed with a bunch of Graphical Statistics, Table and Figures, Data Analysis Representation described in detail with a clear goal to target potential company stakeholders. Including Industry Chain Structure strongly gives out the overview of market growth and it becomes easy to project the hurdles and upsurge profit graphs. Coming to the Competitive landscape this Primary Sclerosing Cholangitis Market report gives out each and every aspect required to size the existing market performance including technological advancements, business overview, positive and negative factors of market position and challenges faced but the market leaders to rank themselves above all. Quality parameters like Primary Sclerosing Cholangitis sales reach, regional coverage, production price trends, and manufacturing cost structure are also studied to give out a perfect competition outlook.

How Does This Market Insights Help?

Primary Sclerosing Cholangitis Market share (regional, product, application, end-user) both in terms of volume and revenue along with CAGR

Key factors which are driving this market and restraining its growth

What all challenges manufacturers will face as well as new opportunities and threats faced by them

Learn about the market strategies that are being adopted by your competitors and leading organizations

To gain insightful analyses of the market and have a comprehensive understanding of the “Primary Sclerosing Cholangitis Market” and its commercial landscape

Get Table Of Contents of This Premium Research For Free: https://www.databridgemarketresearch.com/toc/?dbmr=global-primary-sclerosing-cholangitis-market

Major Key Contents Covered in Primary Sclerosing Cholangitis Market:

Introduction of Primary Sclerosing Cholangitis with development and status.

Manufacturing Technology of Primary Sclerosing Cholangitis with analysis and trends.

Analysis of Global Primary Sclerosing Cholangitis market Key Manufacturers with Company Profile, Product Information, Production Information, and Contact Information.

Analysis of Global Primary Sclerosing Cholangitis market Capacity, Production, Production Value, Cost and Profit

Analysis Primary Sclerosing Cholangitis Market with Comparison, Supply, Consumption, and Import and Export.

Primary Sclerosing Cholangitis market Analysis with Market Status and Market Competition by Companies and Countries.

Market Forecast of Global Primary Sclerosing Cholangitis Market with Cost, Profit, Market Shares, Supply, Demands, Import and Export.

Trending factors influencing the market shares of APAC, Europe, North America, and ROW?

Primary Sclerosing Cholangitis Market Analysis of Industry Chain Structure, Upstream Raw Materials, Downstream Industry.

Reasons to Purchase this Report

Current and future of global Primary Sclerosing Cholangitis market outlook in the developed and emerging markets

The segment that is expected to dominate the market as well as the segment which holds the highest CAGR in the forecast period

Regions that are expected to witness the fastest growth rates during the forecast period

The latest development, market shares and strategies that are working by the major market players

A complete value chain of the global Primary Sclerosing Cholangitis market is presented in the research report. It is associated with the review of the downstream and upstream components of the Primary Sclerosing Cholangitis Market. The market is split on the basis of the categories of products and client application segments. The market analysis demonstrates the expansion of each segment of the global Primary Sclerosing Cholangitis market. The research report assists the user in taking a decisive step on the way to be a milestone in growing and expanding their organizations inside the worldwide Primary Sclerosing Cholangitis market.

Some of the Major Highlights of TOC cover:

Chapter 1: Methodology & Scope

Definition and forecast parameters

Methodology and forecast parameters

Data Sources

Chapter 2: Executive Summary

Business trends

Regional trends

Product trends

End-use trends

Chapter 3: Primary Sclerosing Cholangitis Industry Insights

Industry segmentation

Industry landscape

Vendor matrix

Technological and innovation landscape

Chapter 4: Primary Sclerosing Cholangitis Market, By Region

Chapter 5: Company Profile

Business Overview

Financial Data

Product Landscape

Strategic Outlook

SWOT Analysis

In conclusion, the Primary Sclerosing Cholangitis Market report is a reliable source for accessing the research data that is projected to exponentially accelerate your business. The report Give information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis is also incorporated in the report along with speculation attainability inspection and venture return investigation.

For More Information or Query or Customization before Buying, Visit at: https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-primary-sclerosing-cholangitis-market

Customization of the Report:

Data Bridge Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rates

0 notes